The oncogene AEG-1 shows promise as a target for managing chemotherapy-induced peripheral neuropathy, according to a recently published study.

IL-6 blockades with tocilizumab did not improve short-term survival in advanced pancreatic cancer but showed potential ...

In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, ...

Olawaiye noted that the combination is a "well-tolerated regimen and we believe it should be a new standard for platinum-resistant ovarian cancer therapy." Results from the study ...

THP combines one chemotherapy drug (a taxane ... THP (4 cycles of trastuzumab and pertuzumab (HP)) with weekly paclitaxel (12 weeks) or docetaxel (q3w x 4), followed by surgery.

ASCO 2025 overall survival data bolster IMNN-001’s potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of ...

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response  Results, presented simultaneously in oral ...

Pembrolizumab combined with chemoradiation shows promising long-term efficacy and safety in treating advanced non-small cell ...

The widely used chemotherapy drug paclitaxel, commonly known as Taxol, was first extracted from the Pacific yew tree in 1963.